Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- A2 ?, W4 ?7 O" q* x& D
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 - m, T& [& r9 Y5 v( n
+ Author Affiliations% E( V( S1 p& ?- _
$ c! \3 t3 I4 V+ C# s7 I' Q& z
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 T8 K9 X. a Z, J' j2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" Z' V& A& a2 }% j2 D3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan : i9 U! ]' F( M' K
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
6 w" j% y; ~8 Q/ T1 Q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, C) s8 q# v; F2 ^% X/ Z& x- q6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 1 \, \) ]8 j x+ O, H
7Kinki University School of Medicine, Osaka 589-8511, Japan ; Q& A( y' W5 u9 J, y' [
8Izumi Municipal Hospital, Osaka 594-0071, Japan 8 i) i( d) S/ b& H
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan # V4 Y8 d7 ~2 j/ i) L7 }
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
0 h( x, R" c( `6 ?- Y* xAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
* B% s" z6 P4 k2 D8 x" H1 g- C: h! P1 l0 p" v
|